Effect of the class I metabotropic glutamate receptor antagonist AIDA on certain behaviours in rats with experimental chronic hyperammonemia.
OBJECTIVE
This study examines possible interactions between behavioral effects and mGluR1 (class I metabotropic glutamate receptor) by injecting AIDA [(RS)-1-aminoindan-1,5-dicarboxylic acid] in rats with experimental chronic hyperammonemia (chHA).


METHODS
The effects of mGluR1 antagonist on some behaviors were tested in control groups of rats and in rats with chHA. Experimental chHA was induced by intraperitoneal injection of ammonium acetate (12 mmol/kg) for five consecutive days. We used the following behavioural tests: the open field test, the passive avoidance test and the elevated "plus" maze.


RESULTS
In control rats AIDA administered intracerebroventricularly (i.c.v.) at the dose 100 nmol decreased the number of crossings and bar approaches in the open field test and impaired acquisition and recall in the passive avoidance situation. ChHA significantly inhibited locomotor and exploratory activity and profoundly impaired acquisition and recall processes in the passive avoidance test and significantly increased acute stress responses. AIDA increased locomotor activity in chHA rats (especially number of crossed fields and rearings) and produced anxiety enhancement in rats with chHA. AIDA used in rats with chHA significantly improved acquisition and retrieval processes.


CONCLUSIONS
The obtained results suggest that AIDA, the antagonist of mGluR1, had beneficial effects on learning and memory in rats with experimental chronic hyperammonemia.
Grzeda
E
E
Department of Pharmacology, Medical University of Białystok, Białystok, Poland.
Wiśniewska
R J
RJ
D000085:Acetates / Q000009:adverse effects; D000818:Animals; D001007:Anxiety / Q000523:psychology; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D002908:Chronic Disease; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005106:Exploratory Behavior / Q000187:drug effects; D022124:Hyperammonemia / Q000188:drug therapy* / Q000523:psychology; D007189:Indans / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008124:Locomotion / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D011939:Mental Recall / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D013315:Stress, Psychological / Q000523:psychology
C095756:1-aminoindan-1,5-dicarboxylic acid; D000085:Acetates; D018691:Excitatory Amino Acid Antagonists; D007189:Indans; D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1; C018824:ammonium acetate